Research Appraisals
Evidence-based critical appraisals of the latest medical research, systematically evaluated using Oxford CEBM methodology.
Showing 2 appraisals
Renal failure
Time-updated explainable machine learning predicts short-term mortality in peritoneal dialysis patients
Objective: This study aimed to develop and validate a time-updated, explainable machine learning (ML) early-warning system for short-term mortality risk in patients with continuous ambulatory peritoneal dialysis (CAPD). Methods: Multiple supervised ML techniques were validated to stratify individuals at high risk of 6-month death, classifiers were trained, internally validated and independently temporally validated in this retrospective study of 1,484 CAPD patients in our PD center. We collected time-updated markers such as patient demographics, clinical characteristics, and laboratory data to inform the ML models and the performance of eight ML models was assessed via the area under the curve (AUC) and accuracy. The SHapley Additive exPlanation (SHAP) method was selected to further interpret the predictive models and link findings to clinical actionability. Results: In internal validation cohort, the light gradient boosting machine (lightGBM) model demonstrated best performance with AUC of 0.888 and highest accuracy of 0.879. In temporal validation cohort, the lightGBM model also exhibited good classification performance, achieving AUC of 0.850 and good accuracy of 0.874. Moreover, SHAP analysis identified several key features that contributed to the accurate prediction of the lightGBM model. Conclusions: The time-updated lightGBM early-warning system helps clinicians to early identify CAPD patients with high risk of death within six months based on easily accessible and time-updated data and provides a basis for personalized treatment. We developed and validated a time-updated, explainable ML early-warning system that accurately predicts 6-month all-cause mortality in CAPD patients using routinely, available laboratory data.The LightGBM model achieved excellent discriminative performance, with an AUC of 0.888 in internal validation and 0.850 in independent temporal validation.This model provides a scalable, low-cost early-warning tool for routine CAPD care, with a standardized risk-stratified intervention framework to guide timely, targeted care and advance care planning.
29 May 2026
Read appraisal →BMC nephrology
Roxadustat for CKD-related anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis
BACKGROUND: CKD-related anemia remains a major complication in patients receiving peritoneal dialysis (PD), with limited treatment options beyond erythropoiesis-stimulating agents. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, has shown promise in correcting CKD-related anemia and modulating iron and metabolic parameters. However, its evidence in PD remains limited. METHODS: We conducted a systematic search of PubMed, Scopus, and Web of Science from inception to July 20, 2025. We included studies reporting the efficacy and safety of roxadustat in PD. Statistical analysis was performed using Review Manager (RevMan 5.4 for Windows) and R Studio. RESULTS: Eight studies were included in the meta-analysis (n = 607). Roxadustat significantly increased hemoglobin at all time points (MD 0.35 g/dL, 95% CI 0.28-0.41; p < 0.00001), serum iron (MD 0.95 µmol/L, 95% CI 0.02-1.89; p = 0.05), and total iron-binding capacity (MD 6.25 µmol/L, 95% CI 3.95-8.55; p < 0.00001), and reduced hepcidin (MD - 12.28 ng/mL, 95% CI - 21.06 to - 3.50; p = 0.006). No significant effects were observed for ferritin (p = 0.49), transferrin saturation (p = 0.45), cholesterol (p = 0.07), LDL (p = 0.14), HDL (p = 0.27), triglycerides (p = 0.26), CRP (p = 0.75), systolic blood pressure (p = 0.10), or diastolic blood pressure (p = 0.08). Heterogeneity was low to moderate for most outcomes. CONCLUSION: Roxadustat is effective in improving hemoglobin and iron metabolism in patients with PD, while exerting neutral effects on lipids, inflammation, and blood pressure. These findings support its role as a promising therapy for CKD-related anemia in PD. CLINICAL TRIAL NUMBER: Not applicable.
28 May 2026
Read appraisal →